(Reuters) – The United States is reviewing reports of a handful of potential cases of severe side effects among people who received Johnson & Johnson’s COVID-19 vaccine in addition to those that led to a pause in its use, a top U.S. public health official said on Monday.
Healthpeak Properties raised its annual funds from operations (FFO) forecast on Thursday, banking on resilient demand for its medical office and life science properties.
Edwards Lifesciences Corp on Thursday reported upbeat first-quarter profit due to strong demand for its artificial heart valves and other medical devices.
ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended…
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the…
The U.S. health regulator has sent a warning letter to Cardinal Health after an inspection of its facility in Illinois found the company was marketing…
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and…
West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to…
Labcorp beat Wall Street expectations for first-quarter profit on Thursday, as growing demand for specialty tests boosted sales at its diagnostics business.
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
Bristol Myers Squibb reported a first-quarter loss on Thursday as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a small…
